二甲双胍与2型糖尿病患者胰腺癌风险及预后相关性的Meta分析

A Meta-Analysis of the Relationship Between Metformin and Risk and Prognosis of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus

目的:探讨糖尿病患者口服二甲双胍与胰腺癌发生风险及预后的关系。方法:利用PubMed、EMbase、Cochrance图书馆、维普、万方与中国知网等8个检索网站对国内外公开发表的关于二甲双胍与2型糖尿病发生胰腺癌风险及预后的相关文献进行检索。检索时限为2010年1月1日-2020年11月19日,统计分析使用STATA 15.0软件。结果:纳入文献共13篇,与非二甲双胍组相比,二甲双胍与2型糖尿病患者发生胰腺癌的风险无明显相关性[OR=0.89,95%CI(0.66~1.20),P=0.433];总生存期方面,2型糖尿病合并胰腺癌二甲双胍组与非二甲双胍组存在显著差异[HR=0.74,95%CI(0.61~0.91),P=0.003]。结论:使用二甲双胍不会增加2型糖尿病患者发生胰腺癌的风险,且能够延长2型糖尿病合并胰腺癌的生存期。

Objective:To investigate the relationship between metformin and pancreatic cancer risk and progno-sis in diabetic patients.Methods:Eight search websites including PubMed,EMbase,Cochrance Library,VIP,Wanfang and CNKI were used to search the relevant literatures published at home and abroad on the risk and prognosis of pancreatic cancer in metformin and type 2 diabetes mellitus.The search period was from January 1,2010 to November 19,2020.Statistical analysis was performed using STATA 15.0 software.Results:A total of 13 articles were included.Compared with the non-metformin group,the use of metformin was not associated with the risk of pancreatic cancer in patients with type 2 diabetes[OR=0.89,95%CI(0.66-1.20),P=0.433].In terms of overall survival,there was a significant difference between the metformin group and the non-metformin group in type 2 diabetes mellitus complicated with pancreatic cancer[HR=0.74,95%CI(0.61-0.91),P=0.003].Conclusion:Metformin can significantly improve the prognosis of type 2 diabetes mellitus complicated with pancreatic cancer.However,metformin use was not associated with pancreatic cancer risk in patients with type 2 diabetes.